Physician profile
Joseph Dai
NPI 1831355700
$6,608.17
in general payments reported to CMS, 2019-2025
28 companies · $2,494 in 2025
The $2,494 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $45.69 · 2021: $284 · 2022: $612 · 2023: $988 · 2024: $1,564 · 2025: $2,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,946 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,945.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,050.47 | 2023-2025 | Via Matrix, Novachor, Puraply |
| Novartis Pharmaceuticals Corporation | $809.53 | 2019-2025 | |
| Genzyme Corporation | $791.98 | 2021-2025 | |
| Abbvie INC. | $738.58 | 2019-2025 | Skyrizi, Rinvoq |
| Galderma Laboratories, L.P. | $489.45 | 2021-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $436.60 | 2023-2025 | Sotyktu |
| Amgen INC. | $252.36 | 2022-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $234.78 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $214.45 | 2022-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $191.95 | 2022-2025 | |
| Kerecis Limited | $161.67 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Incyte Corporation | $161.05 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $160.46 | 2023-2025 | Dupixent |
| Almirall LLC | $122.15 | 2019 | |
| Pfizer INC. | $122.01 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $97.33 | 2019 | |
| Stemline Therapeutics INC. | $95.07 | 2019 | |
| Lilly USA, LLC | $87.26 | 2021-2025 | Ebglyss, Taltz |
| Ucb, INC. | $86.97 | 2023-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $55.95 | 2023-2025 | Cabtreo, Arazlo, Jublia |
| Convatec INC. | $44.85 | 2025 | |
| Epi Health, LLC | $41.79 | 2022 | |
| Dermavant Sciences, INC. | $40.93 | 2023-2024 | Vtama |
| Organon LLC | $33.60 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $27.85 | 2025 | |
| Botanix Sb INC | $21.16 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $19.86 | 2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $18.06 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Dai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.